Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.685
Peer-review started: December 11, 2023
First decision: December 14, 2023
Revised: December 19, 2023
Accepted: January 17, 2024
Article in press: January 17, 2024
Published online: February 21, 2024
Processing time: 71 Days and 15.9 Hours
In clinical practice, the availability of non-invasive tools predicting the first decompensation event (DE) in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-related compensated advanced chronic liver disease (cACLD) context is still an unmet need.
Red cell distribution width to platelet ratio (RPR) has been recently shown to predict fibrosis in MASLD patients; however, its role in predicting DE has never been explored.
Herein, we investigated the clinical usage of RPR in predicting DEs in MASLD-related cACLD patients.
MASLD-cACLD patients were consecutively enrolled and followed up for 3 years. Biochemical, clinical, and Liver Stiffness Measurement were collected.
RPR accurately predicts [area under the curve (AUC): 0.94; best cut-off 0.472) the first DE in MASLD-cACLD. RPR accurately predicts acute decompensation (AD; AUC: 0.94; best cut-off 0.894) as the first DE in these patients. Patients presenting baseline clinically significant portal hypertension and RPR 0.472 show higher risk (hazard ratio: 3.10) of 3-year decompensation occurrence.
Altogether these findings suggest RPR as a valid and potentially applicable non-invasive tool in the prediction of decompensation in MASLD-related cACLD patients.
The potential availability of RPR as non-invasive, not expensive, and routinely assessable tool in the prediction of timing and modalities of decompensation in MASLD-cACLD patients could remodel the management of these patients.